Not forrelease, publication or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction in which such release, publication or distribution would be unlawful. The important notices at the end of this release must be observed.

PRESS RELEASE

Record quarter for Cantourage: EUR  25.6 millionr evenue in Q1 - for the first time more than EUR 10.7 million revenue in one month

Berlin, April 10, 2025 - Cantourage Group SE (hereinafter “Cantourage”, ISIN:DE000A3DSV01, www.cantourage.com), Europe's leading listed medical cannabis company, has completed the strongest quarter in its history: In the firstquarter of 2025, the company generated sales of EUR 25.6 million - a new record. In the same quarter of the previous year - shortly before cannabis legalization came into force - revenue was EUR 6.1 million. Cantourage has thus more than quadrupled its quarterly revenue year-on-year and further strengthened its market position significantly.

In March2025, the Berlin-based company also generated double-digit monthly revenue for the first time: at EUR 10.7 million, the previous record from December 2024 (EUR 8.5 million) was significantly exceeded.

Demand for Cantourage cannabis flowers continues to grow

The continued strong increase in demand for Cantourage cannabis flowers is clearly reflected in the company's revenue performance: in 2024 as a whole, the company generated revenue of EUR 51.4 million, which corresponds to an increase of 118% compared to the previous year (2023: EUR 23.6 million). In order to keep up with this momentum, Cantourage has made targeted investments in the expansion of its processing capacities in Germany and Portugal. At the same time, existing partnerships with growers worldwide - particularly in Canada - were systematically expanded, creating more and more supply. Demand for Cantourage cannabis flowers in Poland and the UK also remains high and continues to grow. As the European market leader, Cantourage is thus benefiting from Europe-widegrowth and increasing interest in cannabis therapies.

PhilipSchetter, CEO of Cantourage, says: "The first quarter of 2025 marked asignificant milestone for us - we set a new record with sales of over 26million euros. We are particularly proud of March: for the first time in our company's history, we were able to achieve double-digit monthly revenue. This impressively demonstrates that our scalable business model is working and thatour capacity expansions are taking effect. The strong demand for our products -not only in Germany, but also in Poland and the UK - confirms our strategicdirection.
While other market participants are confronted with the current uncertainties and tariffs in the US market, we are benefiting from our clear focus on Europe. Our operating business is largely independent of developments in the USA. Instead, we are continuing to expand our global supply chain - in particular by working closely with leading cultivation partners in Canada - in order to consolidate our market leadership in Europe in the long term. The CDU/CSU and SPD have presented their coalition agreement - we welcome the fact that the Cannabis Act will be evaluated in order to make any necessary adjustments inthe future. The current regulations have already noticeably improved the supplyof cannabis from pharmacies: barriers have been removed, especially fordoctors, pharmacists and patients - this path should be pursued further."

About Cantourage

Cantourage is a leading European company for the production and distribution of medical cannabis. Cantourage enables growers worldwide to sell products in European medical markets. Founded in 2019, the company works with more than 60 cannabis growers from 18 countries. Cantourage ensures the highest pharmaceutical quality standards along the value chain and offers products in all relevant market segments: dried flowers, extracts, dronabinol and cannabidiol. The company has been listed on the Frankfurt Stock Exchange since November 11, 2022 and is listed under the ticker symbol “HIGH”.

Presscontacts

Pia Senkel |pia.senkel@tonka-pr.com | +49 (0) 173 3702649

Klaas Geller| klaas.geller@tonka-communications.de | +49 (0) 176 74717519

This announcement does not constitute an offer to the public or a solicitation of anoffer to sell securities to the public, in particular not within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).

‍